Literature DB >> 31240269

Redox Signaling in Sickle Cell Disease.

Deirdre Nolfi-Donegan1, Tirthadipa Pradhan-Sundd2, Kirkwood A Pritchard3, Cheryl A Hillery1.   

Abstract

Sickle cell disease (SCD) is characterized by chronic hemolysis and repeated episodes of vascular occlusion leading to progressive organ injury. SCD is characterized by unbalanced, simultaneous pro-oxidant and anti-oxidant processes at the molecular, cellular and tissue levels, with the majority of reactions tipped in favor of pro-oxidant pathways. In this brief review we discuss new findings regarding how oxidized hemin, hemolysis, mitochondrial dysfunction and the innate immune system generate oxidative stress while hemopexin, haptoglobin, heme oxygenase-1 (HO-1) and nuclear factor erythroid 2-related factor 2 (Nrf2) may provide protection in human and murine SCD. We will also describe recent clinical trials showing beneficial effects of antioxidant therapy in SCD.

Entities:  

Keywords:  hemoglobin; hemolysis; inflammation; oxidative stress; sickle cell disease

Year:  2019        PMID: 31240269      PMCID: PMC6592428          DOI: 10.1016/j.cophys.2019.04.022

Source DB:  PubMed          Journal:  Curr Opin Physiol        ISSN: 2468-8673


  47 in total

1.  Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation.

Authors:  Tian Lin; Fatima Sammy; Huan Yang; Sujatha Thundivalappil; Judith Hellman; Kevin J Tracey; H Shaw Warren
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

2.  Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.

Authors:  John D Belcher; Chunsheng Chen; Julia Nguyen; Ping Zhang; Fuad Abdulla; Phong Nguyen; Trevor Killeen; Pauline Xu; Gerry O'Sullivan; Karl A Nath; Gregory M Vercellotti
Journal:  Antioxid Redox Signal       Date:  2016-03-30       Impact factor: 8.401

3.  Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease.

Authors:  Stéphane M Camus; João A De Moraes; Philippe Bonnin; Paul Abbyad; Sylvain Le Jeune; François Lionnet; Laurent Loufrani; Linda Grimaud; Jean-Christophe Lambry; Dominique Charue; Laurent Kiger; Jean-Marie Renard; Claire Larroque; Hervé Le Clésiau; Alain Tedgui; Patrick Bruneval; Christina Barja-Fidalgo; Antigoni Alexandrou; Pierre-Louis Tharaux; Chantal M Boulanger; Olivier P Blanc-Brude
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

4.  Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli.

Authors:  Margaret F Bennewitz; Maritza A Jimenez; Ravi Vats; Egemen Tutuncuoglu; Jude Jonassaint; Gregory J Kato; Mark T Gladwin; Prithu Sundd
Journal:  JCI Insight       Date:  2017-01-12

5.  MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease.

Authors:  Biaoru Li; Xingguo Zhu; Christina M Ward; Athena Starlard-Davenport; Mayuko Takezaki; Amber Berry; Alexander Ward; Caroline Wilder; Cindy Neunert; Abdullah Kutlar; Betty S Pace
Journal:  Exp Hematol       Date:  2018-11-06       Impact factor: 3.084

6.  A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.

Authors:  Jo Howard; Claire Jane Hemmaway; Paul Telfer; D Mark Layton; John Porter; Moji Awogbade; Timothy Mant; Daniel D Gretler; Kobina Dufu; Athiwat Hutchaleelaha; Mira Patel; Vincent Siu; Sandra Dixon; Noel Landsman; Margaret Tonda; Joshua Lehrer-Graiwer
Journal:  Blood       Date:  2019-01-17       Impact factor: 22.113

Review 7.  Oxidative pathways in the sickle cell and beyond.

Authors:  Abdu I Alayash
Journal:  Blood Cells Mol Dis       Date:  2017-05-20       Impact factor: 3.039

8.  Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.

Authors:  Kenneth I Ataga; Abdullah Kutlar; Julie Kanter; Darla Liles; Rodolfo Cancado; João Friedrisch; Troy H Guthrie; Jennifer Knight-Madden; Ofelia A Alvarez; Victor R Gordeuk; Sandra Gualandro; Marina P Colella; Wally R Smith; Scott A Rollins; Jonathan W Stocker; Russell P Rother
Journal:  N Engl J Med       Date:  2016-12-03       Impact factor: 91.245

Review 9.  l-Glutamine for sickle cell anemia: more questions than answers.

Authors:  Charles T Quinn
Journal:  Blood       Date:  2018-06-12       Impact factor: 22.113

10.  Inhibition of myeloperoxidase decreases vascular oxidative stress and increases vasodilatation in sickle cell disease mice.

Authors:  Hao Zhang; Hao Xu; Dorothee Weihrauch; Deron W Jones; Xigang Jing; Yang Shi; David Gourlay; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  J Lipid Res       Date:  2013-08-16       Impact factor: 5.922

View more
  5 in total

1.  Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease.

Authors:  Panae Noomuna; Mary Risinger; Sitong Zhou; Katie Seu; Yuncheng Man; Ran An; Daniel A Sheik; Jiandi Wan; Jane A Little; Umut A Gurkan; Francesco M Turrini; Theodosia Kalfa; Philip S Low
Journal:  Br J Haematol       Date:  2020-04-28       Impact factor: 6.998

Review 2.  Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model.

Authors:  Tirthadipa Pradhan-Sundd; Gregory J Kato; Enrico M Novelli
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-27       Impact factor: 5.282

3.  Biophysical and rheological biomarkers of red blood cell physiology and pathophysiology.

Authors:  Umut A Gurkan
Journal:  Curr Opin Hematol       Date:  2021-05-01       Impact factor: 3.284

Review 4.  Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease.

Authors:  Robert P Hebbel; Gregory M Vercellotti
Journal:  Am J Hematol       Date:  2021-08-23       Impact factor: 13.265

5.  Post-translational modification as a response to cellular stress induced by hemoglobin oxidation in sickle cell disease.

Authors:  Michael Brad Strader; Sirsendu Jana; Fantao Meng; Michael R Heaven; Arun S Shet; Swee Lay Thein; Abdu I Alayash
Journal:  Sci Rep       Date:  2020-08-26       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.